BioMarin’s hemophilia gene therapy still prevents bleeding at four years

BioMarin’s hemophilia gene therapy still prevents bleeding at four years

STAT Plus: BioMarin’s hemophilia gene therapy continues to prevent bleeding at four years

By MATTHEW HERPER AND DAMIAN GARDE

ADOBE

BioMarin’s experimental hemophilia gene therapy, expected to be approved in the U.S. this year, still prevents bleeding in patients treated four years ago.

READ MORE